The global Pcos Diagnostic Market is estimated to be valued at US$ 3.53 Bn in 2023 and is expected to exhibit a CAGR of 5.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:-
Polycystic ovary syndrome (PCOS) is a hormonal disorder common among women of reproductive age. It requires diagnosis of presence of cysts in ovaries and other metabolic defects. Diagnostic tests help identifying symptoms and suitable treatment options.
Market key trends:-
Growing adoption of telehealth for PCOS diagnosis is a key trend in the market. Due to covid-19 pandemic and social distancing measures, demand for remote healthcare services increased significantly. Various players are offering telehealth consultations, online appointments and diagnostic services for PCOS through their websites and mobile applications. This allow patients to consult doctors and undergo initial diagnosis from the comfort of their homes, reducing health risks. For example, PCOS.com provides online PCOS screening and diagnosis by board certified physicians using questionnaires. Such virtual care options are improving access and reducing costs, thereby fueling the diagnostic market growth.
Segment Analysis:-
The global PCOS diagnostic market is segmented on the basis of test type, end-user and region. Based on test type, the market can be segmented into hyperandrogenemia, oligoanovulation & polycystic ovaries. Among these, the hyperandrogenemia segment dominated the global PCOS diagnostic market in 2021 owing to high test volume for early diagnosis and disease monitoring. Based on end-user, the market is segmented into hospitals, diagnostic centers and others. The diagnostic centers segment dominated the market in 2021 due to availability of advanced diagnostic facilities at affordable costs.
Key Takeaways:-
Market size:-
The Global Pcos Diagnostic Market Demand is expected to witness high growth, exhibiting CAGR of 5.0% over the forecast period, due to increasing awareness about early disease diagnosis and rising healthcare expenditure.
Regional analysis:-
North America dominated the global PCOS diagnostic market in 2021 and is expected to continue its dominance over the forecast period. This is attributed to increasing healthcare expenditure, presence of advanced diagnostic facilities and growing prevalence of PCOS in the region.
Key players:-
Key players operating in the Pcos Diagnostic Market include Roche Diagnostics, Abbott Laboratories, Quest Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Bio-Rad Laboratories, Agilent Technologies, Hologic, F. Hoffmann-La Roche Ltd., IGENOMIX, Myriad Genetics, Ansh Labs, Diagnostica Stago, Beckman Coulter, Inc., and Randox Laboratories Ltd. These players are focusing on new product launches, collaborations and expansions to increase their market share in the Pcos Diagnostic Market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it